Trigeek wrote: Hey gals I finished my Dose Dense 4 X ac and 4 X taxol .. I have a meeting with my oncologist today and he I believe is planning to put me on tamoxifen. I am 45 and was premenaupausal ( well I am now in the deep trenches of chemaupause with insomnia and night flashes galore !! )I have been hearing that some gals have been put on Femara instead of tamox.. Any studies regarding comparing the efficacy of them compared to teach other ? Aylin Mar 20, 2008 PM Liz M wrote: You need to ensure you are postmenopausal before starting on an aromatase inhibitor (Femara/Arimidex/Aromasin). With that said Femara has been shown to be slightly more effective at preventing recurrence than Tamoxifen in ALL studies, including those in which Femara was given as first hormone therapy right after surgery. I was 49 at diagnosis and premenopausal and chemo put me in chemopause. My oncologist wanted me to go on Tamoxifen for 2 to 3 years and then switch to Arimidex or Femara. I chose to remove my ovaries and create a menopausal state in order to take an aromatase inhibitor. Many postmenopausal women take hormonal therapy medicine – either an aromatase inhibitor or tamoxifen – after breast cancer surgery and other treatments for hormone-receptor-positive, early-stage breast cancer. Hormonal therapy medicine can reduce the risk of the cancer coming back (recurrence). A new analysis of results from the BIG 1-98 trial found that the aromatase inhibitor Femara (chemical name: letrozole) improved both disease-free survival (living without the cancer growing) and overall survival (living whether or not the cancer grew) compared to tamoxifen in postmenopausal women diagnosed with estrogen-receptor-positive, HER2-negative breast cancer. The benefits of Femara over tamoxifen were most notable in treating lobular breast cancer compared to ductal breast cancer. Femara was also better at treating luminal B breast cancers with a high level of the protein Ki-67, which helps breast cancer cells grow. The study, "Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial," was presented at the 2012 San Antonio Breast Cancer Symposium. Lobular breast cancer is breast cancer that begins in the milk-producing lobules, which empty out into the milk ducts that carry milk to the nipple. Doxycycline petsmart Where to buy xenical in australia Propranolol and migraine Cheap kamagra pattaya In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of. Femara vs. Tamoxifen for Breast Cancer. Femara, Tamoxifen Show Equal Survival Rates in Breast Cancer Study. The new study shows that the drugs' side effects were in line with known risks; no. Metabolism of letrozole is partly mediated via CYP2A6 and CYP3A4. Cimetidine, a weak, unspecific inhibitor of CYP450 enzymes, did not affect the plasma concentrations. After a median of 8 years of follow-up from a large randomized trial, women with estrogen receptor positive breast cancer who received 5 years of treatment with the aromatase inhibitor letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen. In addition, 5 years of sequential treatment—either 2 years of letrozole followed by 3 years of tamoxifen or 2 years of tamoxifen followed by 3 years of letrozole—was not better than 5 years of letrozole alone at preventing recurrence or death. These results, from the BIG 1-98 trial, were published online October 20, 2011 in Lancet Oncology. Researchers from 27 countries enrolled 8,010 postmenopausal women with invasive breast cancer that could be removed surgically in the trial. After surgery, the women were randomly assigned to one of four groups: 5 years of letrozole (letrozole monotherapy), 5 years of tamoxifen (tamoxifen monotherapy), or one of the two sequential treatment groups. Novartis, the maker of letrozole, provided funding for the trial, along with NCI and the International Breast Cancer Study Group. In 2005, preliminary results from the trial showed that letrozole alone was better than tamoxifen at preventing early recurrences, and when given the option to cross over, 619 of the 2,459 women in the tamoxifen-only arm chose to cross over to receive letrozole. "Taking hormonal drugs for up to 15 years reduces the risk of breast cancers coming back," BBC News reports. A new study looked at 1,918 postmenopausal women with what is known as oestrogen receptor-positive (or ER ) breast cancers – where cancer growth is stimulated by the hormone oestrogen. A class of drugs known as aromatase inhibitors are often used in such cases, as they are able to reduce the production of oestrogen. The women had previously responded well to a five-year course of hormone treatments. They were randomised into two groups: either they took an aromatase inhibitor called letrozole for another five years, or they were given a dummy treatment (placebo). Disease-free survival after five years was 95% in the treatment group and 91% in the placebo group. Extended aromatase inhibitor treatment cut the risk of recurrent or new breast cancer development by about a third. Tamoxifen vs letrozole side effects Letrozole versus tamoxifen in the treatment of advanced breast., Femara vs. Tamoxifen for Breast Cancer - WebMD Cialis costcoCiprofloxacin wikiPropranolol 20 mg side effectsQue es ciprofloxacinSertraline brand name Hi. i had been on Tamoxifen for 8 years and will switch to Letrozole as one of my seconday breast cancer BC spreaded to sternum treatments. to me, tamoxifen side effects is nothing. only hair thinning and slow growth need hair cut once every 9 months. Side effects of Tamoxifen compared to Letrozole - Breast.. Femara - Summary of Product Characteristics. Arimidex vs. Femara for Breast Cancer Differences & Side Effects. Compare Femara vs Tamoxifen head-to-head for uses, ratings, cost, side effects, interactions and more. Femara rated 6.9/10 vs Tamoxifen rated 6.2/10 in overall patient satisfaction. Femara vs Tamoxifen Comparison - Anastrozole Arimidex and letrozole Femara are both aromatase inhibitors, anti-cancer medications used for treating postmenopausal women with breast cancer. Side effects of anastrozole and letrozole that are similar include nausea, vomiting, and headache. Learn more about uses, dosage and side effects. BackgroundTreatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone.